[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363930-105":59,"doc-detail-363930-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","systemic-therapy-for-gastroenteropancreatic-neuroendocrine-neoplasms-current-landscape-and-future-directions","Systemic therapy for gastroenteropancreatic neuroendocrine neoplasms: current landscape and future directions","","Neuroendocrine neoplasms (NENs) are heterogeneous tumors arising from neuroendocrine cells across multiple organs, most commonly the gastrointestinal tract and pancreas, with additional occurrence in the lungs. Using the 2022 WHO framework, NENs are separated into well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs), with NETs further graded by Ki-67 into G1, G2, and G3. Gastroenteropancreatic NENs form the majority of cases and represent an important focus of systemic therapy research. The review synthesizes current systemic treatment options, recent advances, and their biological mechanisms, while outlining unmet clinical needs for unresectable disease.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/systemic-therapy-for-gastroenteropancreatic-neuroendocrine-neoplasms-current-landscape-and-future-directions/363930/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/systemic-therapy-for-gastroenteropancreatic-neuroendocrine-neoplasms-current-landscape-and-future-directions/363930.png","ImageObject",300,407,{"name":92,"@type":93},"awa","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How are gastroenteropancreatic neuroendocrine neoplasms classified under the 2022 WHO system?","Question",{"text":112,"@type":113},"NENs are categorized as well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs). NETs are further subdivided into G1, G2, and G3 based on the Ki-67 index.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What systemic treatment options are standard for unresectable GEP-NETs versus GEP-NECs?",{"text":117,"@type":113},"Unresectable GEP-NETs are treated with hormonal therapy, molecular-targeted therapy, cytotoxic chemotherapy, and peptide receptor radionuclide therapy. Cytotoxic chemotherapy remains the standard of care for unresectable GEP-NECs.",{"name":119,"@type":110,"acceptedAnswer":120},"Why does therapeutic development remain challenging for unresectable NENs?",{"text":121,"@type":113},"Clinical outcomes are described as unsatisfactory, partly because unresectable NENs are rare. This rarity limits evidence and underscores the need for further systemic therapy advances.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},363930,1790467509,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":26,"preview_page_count":19,"preview_urls":145},3985747858093,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","TherapeuTic advances in  \nMedical Oncology Review  \n\n| Systemic therapy for gastroenteropancreatic neuroendocrine neoplasms: current landscape and future directions\u003Cbr>Eiichiro So, Chigusa Morizane and Takuji Okusaka\u003Cbr>Abstract: Neuroendocrine neoplasms (NENs) are a heterogeneous group of tumors arising from neuroendocrine cells located in various organs, most commonly the gastrointestinal tract and pancreas, followed by the lungs. According to the 2022 World Health Organization (WHO) classification, NENs are categorized into well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs) based on morphological differentiation, with NETs further subdivided into G1, G2, and G3 according to the Ki-67 index. Among these, gastroenteropancreatic NENs (GEP-NENs) account for most cases and have become an important area of therapeutic investigation. As understanding of the disease has deepened, various treatment modalities have been developed, and treatment strategies tailored to specific subtypes have become increasingly complex. Currently, the treatment selection for GEP-NENs is largely based on the WHO classification. Hormonal therapy, molecular-targeted therapy, cytotoxic chemotherapy, and peptide receptor radionuclide therapy are standard treatment options for unresectable GEP-NETs, whereas cytotoxic chemotherapy remains the standard of care for GEP-NECs. However, therapeutic development and clinical outcomes remain unsatisfactory in unresectable NENs because of their rarity, highlighting the need for further therapeutic advancements in systemic therapy. In this review, we summarize the current landscape of systemic therapies, recent therapeutic advances, and their underlying biological mechanisms in GEP-NENs, while discussing the ongoing challenges and future directions in the field.\u003Cbr>Keywords: chemotherapy, gastroenteropancreatic neuroendocrine neoplasm, neuroendocrine carcinoma, neuroendocrine neoplasm, neuroendocrine tumor\u003Cbr>Received: 8 March 2026; revised manuscript accepted: 28 June 2026. |  | TherAdv Med Oncol 2026, Vol. 18: 1–24\u003Cbr>DOI: 10. 1177/\u003Cbr>17588359261471127 © The Author(s), 2026. Article reuse guidelines:\u003Cbr>[sagepub.com/journals](sagepub.com/journals)permissions\u003Cbr>Correspondence to:\u003Cbr>Chigusa Morizane\u003Cbr>Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 Japan\u003Cbr>[cmorizan@ncc.go.jp](cmorizan@ncc.go.jp)\u003Cbr>Eiichiro So\u003Cbr>Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Chuo-ku Tokyo, Japan\u003Cbr>Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Minato, Tokyo, Japan\u003Cbr>Takuji Okusaka\u003Cbr>Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Chuo-ku Tokyo, Japan |\n| --- | --- | --- |\n| Introduction\u003Cbr>Neuroendocrine neoplasms (NENs) are a heterogeneous group of tumors that arise from neuroendocrine cells distributed throughout various organs, most commonly in the gastrointestinal tract and pancreas, followed by the lungs.1 According to the Surveillance, Epidemiology, and End Results database, the age-adjusted incidence rate of NENs increased 5.2-fold from 1975 (1.64 per 100,000 persons) to 2021 (8.52 per 100,000 persons) .1 In Japan, a nationwide survey on gastroenteropancreatic (GEP)-NENs reported an annual incidence rate of 2.69 per 100,000 persons in 2010, representing a 1.2-fold increase | compared with that in 2005.2 A recent population-based study demonstrated that the annual incidence rate of GEP-NENs increased to 3.56 per 100,000 individuals in 2016.3 This gradual increase in incidence is thought to reflect advancesin diagnostic modalities and increased awareness of the disease.4,5\u003Cbr>According to the 2022 World Health Organization (WHO) classification, NENs are categorized as well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroe","cbCaimmb8GTKiHvX","https://ap.wps.com/l/cbCaimmb8GTKiHvX","pdf",2001061,24,"English","# Introduction\n## Classification and epidemiology of NENs\n## Therapeutic modalities and treatment selection principles","[{\"question\":\"How are gastroenteropancreatic neuroendocrine neoplasms classified under the 2022 WHO system?\",\"answer\":\"NENs are categorized as well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs). NETs are further subdivided into G1, G2, and G3 based on the Ki-67 index.\"},{\"question\":\"What systemic treatment options are standard for unresectable GEP-NETs versus GEP-NECs?\",\"answer\":\"Unresectable GEP-NETs are treated with hormonal therapy, molecular-targeted therapy, cytotoxic chemotherapy, and peptide receptor radionuclide therapy. Cytotoxic chemotherapy remains the standard of care for unresectable GEP-NECs.\"},{\"question\":\"Why does therapeutic development remain challenging for unresectable NENs?\",\"answer\":\"Clinical outcomes are described as unsatisfactory, partly because unresectable NENs are rare. This rarity limits evidence and underscores the need for further systemic therapy advances.\"}]","Systemic therapy for gastroenteropancreatic neuroendocrine neoplasms: current landscape and future directions | PDF",1790154234,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4cdb56bd73282a3588c4d77a5ba0aea8.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6ee847ba5880e430b234378de112be19.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6f46dffa3139aae1bca996a71f5620cd.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0d13bbac5ef754dacdca8345802219f1.webp",980,1306]